October 5, 2018

Solid Biosciences to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan Capital Markets 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 7:30 am ET in New York City. 

The Chardan Genetic Medicines Conference will be webcast live under the investor relations section of Solid Biosciences’ website at www.solidbio.com and will be archived there following the presentation for 30 days.

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.

Media Contact:
Solid Biosciences
Kate Niazi-Sai
617-337-4680
media@solidbio.com

Investor Contact:
Kendall Investor Relations
Carlo Tanzi, Ph.D.
617-337-4680
investors@solidbio.com

SolidBioLogoDigitalRGB.png

Source: Solid Biosciences Inc.

Related news

Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Jan30

Solid Biosciences Inc. (NASDAQ:SLDB), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per share.

Jan25

Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000.

Nov30

Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.

Sep20

Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 

Jun07
  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.
May11

Solid Biosciences to Initiate Clinical Program for Gene Therapy Candidate in Coming Months

Mar30

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.

Pages

More information about Solid?

Please subscribe to receive our latest news